From my notes on PHRM 3Q06 and 4Q06, they had identical sales of 36.6M. So no real trend down. I believe MGI is using Dacogen sales to show a surprise each quarter. I found a study where PHRM stated very high response rates in AML patients. They had:
14% CR 29% PR 28% Hematologic improvement
However Dacogen has shown the best effect in AML patients and that has been stated several imes by Dr. Manuso. In fact he stated on the approval trial the best response came from AML. This leads me to another point on differences with Vidaza, if Dacogen has the the fastest action and works best in AML patients, well MD's may put more emphasis on progression free. That could be an important reason why Dacogen keeps growing while Vidaza hasn't grown in over a year.